Both in Pharmaceuticals
Upstream Bio vs Rocket Pharmaceuticals
Over the past year UPB returned −70.1% and RCKT returned −21.0%; their daily moves had a correlation of 0.26.
UPB −70.1% RCKT −21.0%Growth of $1, one year, split-adjusted
| Metric | UPB | RCKT |
|---|---|---|
| Price | $5.19 | $2.59 |
| Market cap | $284.3M | $284.3M |
| Today | −2.08% | −0.77% |
| 1 month | −22.4% | −32.9% |
| 6 months | −40.9% | −24.8% |
| Year to date | −80.9% | −26.2% |
| 1 year | −69.9% | −20.6% |
| Revenue growth (YoY) | −17.5% | — |
| Gross margin | 100.0% | — |
| Net margin | −5136.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 90.0× | — |
| Net cash | $261.3M | $262.5M |
| Dividend yield | — | — |
| Volatility (60d) | 55.6% | 61.1% |
| Short % of float | 13.2% | 17.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).